Why Ironwood Pharmaceuticals (IRWD) Stock Is Falling Today

NEW YORK (TheStreet) -- Ironwood Pharmaceuticals (IRWD) was falling -8.2% to $13.63 Tuesday after missing analysts estimates for earnings and revenue for the second quarter.

The company reported a loss of -38 cents a share for the second quarter, missing the Capital IQ Consensus Estimate of -36 cents a share by 2 cents. Revenue fell -29.2$ year-over-year to $6.84 million for the quarter. Analysts expected revenue of $15.75 million in the quarter.

Must read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates IRONWOOD PHARMACEUTICALS INC as a Sell with a ratings score of D. TheStreet Ratings Team has this to say about their recommendation:

"We rate IRONWOOD PHARMACEUTICALS INC (IRWD) a SELL. This is driven by multiple weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The area that we feel has been the company's primary weakness has been its deteriorating net income."

IRWD ChartIRWD data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers

5 Ways Allergan Can Keep Up Momentum

Premarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen

Synergy Pharmaceuticals Secures Approval for Linzess Competitor

Ironwood Pharmaceuticals (IRWD): Today's Weak On High Volume Stock